# Parabilis Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/parabilis-medicines

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.parabilismed.com
- Total disclosed funding: $305M
- Latest round: Series F (Jan 8, 2026)
- Investors on record: 24

## About

Parabilis Medicines, based in the US, specializes in developing innovative peptide therapeutics through its Helicon™ platform, aiming to address unmet needs in oncology and other diseases.Founded in 2016 and headquartered in Cambridge, US, Parabilis Medicines focuses on creating ultra-tunable peptide therapeutics. The company has engaged in two deals and successfully raised USD 305 mn in its Series F funding round, involving notable investors such as ARCH Venture Partners and Fidelity Management. The firm is not a subsidiary of any parent company and has not undergone significant business strategy pivots since its inception.Parabilis Medicines is focused on developing a new class of ultra-tunable peptide therapeutics, primarily through its Helicon™ peptide platform. The company’s core products center around its lead drug candidate, FOG-001 (zolucatetide), which is undergoing clinical development aimed at treating a broad range of tumors. The technology behind these therapeutics enables precise modulation of molecular interactions, which is intended to address significant unmet medical needs in oncology and other serious diseases. Parabilis Medicines aims to provide solutions that have the potential for life-changing impacts on patients and their families, with innovation rooted in a research engine custom-designed to tackle previously insurmountable challenges in drug development. The company targets markets in North America and Europe, ensuring its groundbreaking treatments reach healthcare providers and patients seeking advanced therapeutic options.Parabilis Medicines has recently announced an oversubscribed financing round totaling USD 305 mn to support the ongoing development of FOG-001 and its broader pipeline initiatives. The company's revenue generation strategy is primarily based on partnerships and collaborations with biopharmaceutical companies and research institutions, facilitating joint efforts in clinical trials and product commercialization. Through these partnerships, the company engages in B2B transactions, wherein it licenses its technology and drug candidates to established firms, enabling access to its innovative therapies. The revenue model also includes potential milestone payments tied to the progress of clinical trials and regulatory approvals, as well as royalties on future sales of successful products. The precise pricing structures and specific financial arrangements related to its products are determined collaboratively with partners and are not disclosed publicly.Parabilis Medicines plans to leverage the recent funding of USD 305 mn to accelerate the development of FOG-001 and expand its product pipeline. The company is focused on launching new products, although no specific release dates have been disclosed. Additionally, Parabilis aims to expand its presence in North America and Europe, targeting healthcare markets and potential collaborations with other biopharmaceutical firms to enhance its reach and impact. The funding will support these initiatives, including further clinical trials and regulatory processes.

## Funding rounds

- Series F, Jan 8, 2026, $305M — ARCH Venture Partners, T Rowe Price, General Catalyst Partners, HBM Partners, Marshall Wace, Nextech, Molpus Woodlands Group, GV, Janus Henderson Investors, Foresite Capital, Invus Financial Advisors, VenBio, RA Capital Management, Cormorant Asset Management, Farallon Capital Management, Milky Way Ventures, Samsara BioCapital, Soleus Capital, Fidelity Management and Research Company, Catalio Capital Management, Sixty Degree Capital, Frazier Life Sciences, Alderline Group, Rock Springs Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series F
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series F
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series F
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series F
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series F
- Nextech (https://capitalatlas.ai/funds/nextech) — Series F
- Molpus Woodlands Group — Series F
- GV (https://capitalatlas.ai/funds/gv) — Series F
- Janus Henderson Investors — Series F
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series F
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series F
- VenBio (https://capitalatlas.ai/funds/venbio) — Series F
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series F
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series F
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series F
- Milky Way Ventures (https://capitalatlas.ai/funds/milky-way-ventures) — Series F
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series F
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series F
- Fidelity Management and Research Company — Series F
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series F
- Sixty Degree Capital (https://capitalatlas.ai/funds/sixty-degree-capital) — Series F
- Frazier Life Sciences — Series F
- Alderline Group (https://capitalatlas.ai/funds/alderline-group) — Series F
- Rock Springs Capital — Series F